Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
January 26, 2023 23:45 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a scientific presentation at the 6th Annual DDR...
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
November 23, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Rakovina Therapeutics Inc. Announces Q3 2022 Financial Results and Provides Corporate Update
November 17, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma
November 14, 2022 09:00 ET
|
Rakovina Therapeutics Inc
Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rakovina...
Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
October 31, 2022 08:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations
September 28, 2022 08:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
August 11, 2022 15:09 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Results from Annual General Meeting
June 23, 2022 19:07 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update
May 26, 2022 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas
May 11, 2022 09:00 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...